The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Post Traumatic Stress Disorder Clinical Trial

Official title:

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05312151
• Other study ID #: COMP201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 10, 2022
• Est. completion date: April 2024

Study information

• Verified date: April 2024
• Source: COMPASS Pathways
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder

Description:

The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 22
• Est. completion date: April 2024
• Est. primary completion date: December 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Meet DSM-5 criteria for current PTSD resulting from a trauma experienced during adulthood measured via the PCL-5 in combination with the LEC-5 at screening
• Meet DSM-5 criteria for current PTSD resulting from a trauma experienced during adulthood as assessed by the CAPS, with a minimum score of 25 at baseline
• Able to identify a next of kin who is willing and able to be reached by the investigators in case of emergency
• Have successfully discontinued all prohibited medications at least two weeks prior to baseline visit. For fluoxetine (Prozac), immediate cessation at screening period visit 1a followed by at least four weeks of run-in will be required prior to baseline

Key Exclusion Criteria:

• Current or past history of schizophrenia, schizoaffective disorder or any other form of psychotic disorder, obsessive compulsive disorder, personality disorders, bipolar disorder, or any other significant disorder as assessed by clinician judgement and a structured clinical interview (MINI 7.0.2)
• Diagnosis of complex PTSD according to the International Trauma Questionnaire (ITQ)
• Borderline Personality Disorder as demonstrated by both the McLean Screening Instrument for Borderline Personality Disorder (MSI- BPD) score = 7 and clinical confirmation of diagnosis by the study clinician and Medical Monitor
• Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, during screening or at baseline, or; (2) suicidal behaviours within the past year, or; (3) history of serious suicide attempt that required a rescuing medical intervention, or; (4) clinical assessment of significant suicidal risk during participant interview
• Current (within the last year) alcohol or substance use disorder as informed by DSM-5 assessed via the MINI 7.0.2 at screening
• Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin
• Exposure to 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide (LSD), or peyote in the past year
• Primary diagnosis of major depressive disorder within 6 months of study entry
• Exposure to a traumatic experience in the past 3 months
• Significant childhood physical or sexual abuse based on clinician judgment with the use of CTQ
• Enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 21 days of baseline

Related Conditions & MeSH terms

• Post Traumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Drug:
• Psilocybin
Open label

Locations

Country	Name	City	State
United Kingdom	Kings College London, Institute of Psychiatry, Psychology and Neurology	London
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Sunstone Therapies	Rockville	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
COMPASS Pathways

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Proportion of patients with adverse events (AEs)	Up to 12 weeks
Secondary	Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from baseline	CAPS-5 is a 30 item scale, each item is scored from 0-4; Higher scores denote greater severity for each item	Up to 12 weeks
Secondary	Change in PTSD checklist for DSM-5 (PCL-5) from baseline	PCL-5 is a 20-item self-reported scale, each item is scored from 0-4; Higher scores denote greater severity for each item	Up to 12 weeks
Secondary	Change in Sheehan Disability Scale (SDS) total score from baseline	SDS is a 5-item scale, the total score is from 0 to 30; Higher scores denote greater impairment of function	Up to 12 weeks